284 related articles for article (PubMed ID: 24958181)
21. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
22. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
23. Better Outcomes with Precision Medicine.
Cancer Discov; 2016 Dec; 6(12):1296-1297. PubMed ID: 27784709
[TBL] [Abstract][Full Text] [Related]
24. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
Tian Q; Price ND; Hood L
J Intern Med; 2012 Feb; 271(2):111-21. PubMed ID: 22142401
[TBL] [Abstract][Full Text] [Related]
25. Translating genomics in cancer care.
Bombard Y; Bach PB; Offit K
J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
[TBL] [Abstract][Full Text] [Related]
26. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
27. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
28. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
29. Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream.
Mack SC; Northcott PA
J Clin Oncol; 2017 Jul; 35(21):2346-2354. PubMed ID: 28640705
[TBL] [Abstract][Full Text] [Related]
30. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
31. Identifying molecular drivers of gastric cancer through next-generation sequencing.
Liang H; Kim YH
Cancer Lett; 2013 Nov; 340(2):241-6. PubMed ID: 23178814
[TBL] [Abstract][Full Text] [Related]
32. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
33. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
34. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
35. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough.
Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H
Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192
[TBL] [Abstract][Full Text] [Related]
36. Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care.
Cheng ML; Solit DB
Ann Intern Med; 2018 Feb; 168(3):221-222. PubMed ID: 29310131
[No Abstract] [Full Text] [Related]
37. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
38. The opportunities and challenges of implementing genomics-informed personalized medicine.
Chisholm RL
Clin Pharmacol Ther; 2013 Aug; 94(2):181-2. PubMed ID: 23872829
[No Abstract] [Full Text] [Related]
39. Clinical Perspectives of Single-Cell RNA Sequencing.
Kim N; Eum HH; Lee HO
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439827
[TBL] [Abstract][Full Text] [Related]
40. Direct-to-consumer personal genome testing and cancer risk prediction.
Bellcross CA; Page PZ; Meaney-Delman D
Cancer J; 2012; 18(4):293-302. PubMed ID: 22846729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
